Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats

Neuropharmacology

Volumn 43, Issue 2, 2002, Pages 181-187

  Pilc, A ^a,b   Klodzinska A ^a   Branski P ^a   Nowak, G ^a,b   Palucha A ^a   Szewczyk, B ^a   Tatarczynska E ^a   Chojnacka Wojcik E ^a   Wieronska J M ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

2 Methyl 6 (phenylethynyl) pyridine; Animal models of depression; Anxiety; Conflict drinking test; Convulsions; Depression; mGlu5 receptors; N methyl D aspartic acid; Olfactory bulbectomy

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DESIPRAMINE; DIAZEPAM; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; CONVULSION; DEPRESSION; DRUG EFFECT; MALE; MOUSE; NONHUMAN; OLFACTORY BULBECTOMY; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SHOCK;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; AVOIDANCE LEARNING; DEPRESSION; MALE; MICE; PYRIDINES; RATS; RATS, WISTAR;

EID: 0036669731     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00082-5     Document Type: Article

References (50)

1. Andrews G., Sanderson K., Slade T., Issakidis C. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bulletin of World Health Organisation. 78:2000;446-454.
2. Attucci S., Carla V., Mannaioni G., Moroni F. Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. British Journal of Pharmacology. 132:2001;799-806.
3. Awad H., Hubert G.W., Smith Y., Levey A.I., Conn P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. Journal of Neuroscience. 20:2000;7871-7879.
4. Bajkowska M., Brański P., Śmiałowska M., Pilc A. Effect of chronic antidepressant or electroconvulsive shock treatment on mGLuR1a immunoreactivity expression in the rat hippocampus. Polish Journal of Pharmacology. 51:1999;539-541.
5. Barrett J.E., Barrett J.A., Oxman T.E., Gerber P.D. The prevalence of psychiatric disorders in a primary care practice. Archives of General Psychiatry. 45:1988;1100-1106.
6. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry. 47:2000;351-354.
7. Cairncross K.D., Cox B., Forster C., Wren A.F. Olfactory projection systems, drugs and behaviour: a review. Psychoneuroendocrinology. 4:1979;253-272.
8. Chojnacka-Wójcik E., Kłodzińska A., Pilc A. Glutamate receptor ligands as anxiolytics. Current Opinion in Investigational Drugs. 2:2001;1112-1119.
9. Chojnacka-Wójcik E., Tatarczyńska E., Pilc A. The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. European Journal of Pharmacology. 319:1997;153-156.
10. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annual Review of Pharmacology and Toxicology. 37:1997;205-237.
11. Danysz W., Parsons C.G., Bresnik I., Quack G. Glutamate in CNS Disorders. Drugs News Perspectives. 8:1996;261-277.
12. Doherty A.J., Palmer M.J., Henley J.M., Collingridge G.L., Jane D.E. (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu(5), but not mGlu(1), receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology. 36:1997;265-267.
13. Fitzjohn S.M., Irving A.J., Palmer M.J., Harvey J., Lodge D., Collingridge G.L. Activation of group I mGluRs potentiates NMDA responses in rat hippocampal slices. Neuroscience Letters. 203:1996;211-213.
14. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Velicelebi G., Kuhn R. 2-methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 38:1999;1493-1503.
15. Glaum S.R., Miller R.J. Activation of metabotropic glutamate receptors produces reciprocal regulation of ionotropic glutamate and GABA responses in the nucleus of the tractus solitarius of the rat. Journal of Neuroscience. 13:1993;1636-1641.
16. Glaum S.R., Miller R.J. Acute regulation of synaptic transmission by metabotropic glutamate receptors. Conn P.J., Patel J., The Metabotropic Glutamate Receptors. 1994;147-172 Humana Press, Totowa, NJ.
17. Haefely W., Kulcsar A., Mohler H., Pieri L., Polc P., Schaffner R. Possible involvement of GABA in the central actions of benzodiazepines. Advances in Biochemical Psychopharmacology. (14):1975;131-151.
18. Healy D. The three faces of the antidepressants. Journal of Nervous and Mental Disease. 187:1999;174-180.
19. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., Kallman M.J. Anxiolytic and side-effect profile of LY354740: a potent highly selective, orally active agonist for group II metabotropic glutamate receptors. Journal of Pharmacology and Experimental Therapeutics. 284:1998;651-660.
20. Jancsar S.M., Leonard B.E. Changes in neurotransmitter metabolism following olfactory bulbectomy in the rat. Progress in Neuro-psychopharmacology and Biological Psychiatry. 8:1984;263-269.
21. Jesberger J.A., Richardson J.S. Animal models of depression: parallels and correlates to severe depression in humans. Biological Psychiatry. 20:1985;764-784.
22. Kłodzińska A., Chojnacka-Wójcik E., Pałucha A., Brański P., Popik P., Pilc A. Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology. 38:1999;1831-1839.
23. Kłodzińska A., Tatarczyńska E., Chojnacka-Wójcik E., Pilc A. Anxiolytic-like effects of group I metabotropic glutamate antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) in rats. Polish Journal of Pharmacology. 52:2000;463-466.
24. Leonard B.E., Tuite M. Anatomical physiological, and behavioral aspects of olfactory bulbectomy in the rat. International Review of Neurobiology. 22:1981;251-286.
25. Lloyd K.G., Morselli P.L., Depoortere H., Fournier V., Zivkovic B., Scatton B., Broekkamp C., Worms P., Bartholini G. The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacology, Biochemistry and Behavior. 18:1983;957-966.
26. Mc Geer P.L., Eccles J.C., Mc Geer E.G. Mc Geer P.L., Eccles J.C., Mc Geer E.G., Molecular Neurobiology of the Mammalian Brain. 1987;Plenum Press, New York.
27. Monaghan D.T., Bridges R.J., Cotman C.W. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annual Review of Pharmacology and Toxicology. 29:1989;365-402.
28. Oleary D.M., Movsesyan V., Vicini S., Faden A.I. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. British Journal of Pharmacology. 131:2000;1429-1437.
29. Pilc A., Brański P., Pałucha A., Tokarski K., Bijak M. Antidepressant treatment influences group I of glutamate metabotropic receptors in slices from hippocampal CA1 region. European Journal of Pharmacology. 349:1998;83-87.
30. Pilc, A., Kłodzińska A., Nowak, G., 2002. A role of glutamate in the treatment of anxiety and depression, focus on group I metabotropic glutamate (mGlu) receptors. Drugs of the Future 3, 2002.
31. Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 34:1995;1-26.
32. Pisani A., Gubellini P., Bonsi P., Conquet F., Picconi B., Centonze D., Bernardi G., Calabresi P. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience. 106:2001;579-587.
33. Przegaliński E., Tatarczyńska E., Kłodzińska A., Chojnacka-Wójcik E. Tolerance to anxiolytic- and antidepressant-like effects of a partial agonist of glycineB receptors. Pharmacology, Biochemistry and Behavior. 64:1999;461-466.
34. van Riezen H., Schnieden H., Wren A.F. Olfactory bulb ablation in the rat: behavioural changes and their reversal by antidepressant drugs. British Journal of Pharmacology. 60:1977;521-528.
35. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. Journal of Pharmacology and Experimental Therapeutics. 299:2001;12-20.
36. Skolnick P. Antidepressants for the new millennium. European Journal of Pharmacology. 375:1999;31-40.
37. Skolnick P., Layer R.T., Popik P., Nowak G., Paul I.A., Trullas R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry. 29:1996;23-26.
38. Skolnick P., Legutko B., Li X., Bymaster F.P. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacological Research. 43:2001;411-422.
39. Spooren W.P.J.M., Gasparini F., Salt T.E., Kuhn R. Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. Trends in Pharmacological Sciences. 22:2001;331-337.
40. Spooren W.P.J.M., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., Porsolt R.D., Gentsch C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. Journal of Pharmacology and Experimental Therapeutics. 295:2000;1267-1275.
41. Tatarczyńska E., Kłodzińska A., Chojnacka-Wójcik E., Pałucha A., Gasparini F., Kuhn R., Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. British Journal of Pharmacology. 132:2001;1423-1430.
42. Thomas L.S., Jane D.E., Gasparini F., Croucher M.J. Glutamate release inhibiting properties of the novel mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence. Neuropharmacology. 41:2001;523-527.
43. Thomas L.S., Jane D.E., Harris J.R., Croucher M.J. Metabotropic glutamate autoreceptors of the mGlu(5) subtype positively modulate neuronal glutamate release in the rat forebrain in vitro. Neuropharmacology. 39:2000;1554-1566.
44. Ugolini A., Corsi M., Bordi F. Potentiation of NMDA and AMPA responses by the specific mGluR(5) agonist CHPG in spinal cord motoneurons. Neuropharmacology. 38:1999;1569-1576.
45. Vogel J.R., Beer B., Clody D.E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia. 21:1971;1-7.
46. Vos T., Mathers C.D. The burden of mental disorders: a comparison of methods between the Australian burden of disease studies and the global burden of disease study. Bulletin of World Health Organisation. 78:2000;427-438.
47. Wiley J.L., Cristello A.F., Balster R.L. Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. European Journal of Pharmacology. 294:1995;101-107.
48. Wróblewski J.T., Danysz W. Modulation of glutamate receptors: molecular mechanisms and functional implications. Annual Review of Pharmacology and Toxicology. 29:1989;441-474.
49. Zahorodna A., Bijak M. An antidepressant-induced decrease in the responsiveness of hippocampal neurons to group I metabotropic glutamate receptor activation. European Journal of Pharmacology. 386:1999;173-179.
50. Zimmerman M., McDermut W., Mattia J.I. Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. American Journal of Psychiatry. 157:2000;1337-1340.